Full Text Journal Articles by
Author Paulus Kirchhof

Advertisement

Find full text journal articles






Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W Weiss, Johannes Waltenberger, Jan Steffel, Joris R de Groot, Pierre Levy, Ameet Bakhai, Wolfgang Zierhut, Petra Laeis, Michael Kerschnitzki, Paul-Egbert Reimitz, Paulus Kirchhof, ,

BACKGROUND:Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The available routine care data have demonstrated the safety of different NOACs; however, such data for edoxaban are scarce. Here, we report baseline characteristics of ... Read more >>

BMC Cardiovasc Disord (BMC cardiovascular disorders)
[2019, 19(1):165]

Cited: 0 times

View full text PDF listing >>



Education as a vehicle towards quality improvement in the European Society of Cardiology.

Paulus Kirchhof, Ronen Beeri, Kevin Fox, Julia Grapsa, Dipak Kotecha,

Cardiovasc. Res. (Cardiovascular research)
[2019, 115(8):e80-e81]

Cited: 0 times

View full text PDF listing >>



Advertisement

Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States.

Mohamed Osama Mohamed, Paulus Kirchhof, Mladen Vidovich, Michael Savage, Muhammad Rashid, Chun Shing Kwok, Mark Thomas, Omar El Omar, Fakhr Al Ayoubi, David L Fischman, Mamas Andreas Mamas,

Atrial fibrillation (AF) is the most common arrhythmia in patients presenting with acute coronary syndrome (ACS). The present study examined the rates and trends of clinical outcomes and management strategies of non-ST-elevation ACS (NSTE-ACS) related hospitalizations in the United States, in patients with concomitant AF compared with those in sinus ... Read more >>

Am. J. Cardiol. (The American journal of cardiology)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset.

Winnie Chua, Christina L Easter, Eduard Guasch, Alice Sitch, Barbara Casadei, Harry J G M Crijns, Doreen Haase, Stéphane Hatem, Stefan Kääb, Lluis Mont, Ulrich Schotten, Moritz F Sinner, Karla Hemming, Jonathan J Deeks, Paulus Kirchhof, Larissa Fabritz,

BACKGROUND:Atrial fibrillation (AF) is caused by different mechanisms but current treatment strategies do not target these mechanisms. Stratified therapy based on mechanistic drivers and biomarkers of AF have the potential to improve AF prevention and management outcomes. We will integrate mechanistic insights with known pathophysiological drivers of AF in models ... Read more >>

BMC Cardiovasc Disord (BMC cardiovascular disorders)
[2019, 19(1):120]

Cited: 0 times

View full text PDF listing >>



Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.

Hans-Christoph Diener, Ralph L Sacco, J Donald Easton, Christopher B Granger, Richard A Bernstein, Shinichiro Uchiyama, Jörg Kreuzer, Lisa Cronin, Daniel Cotton, Claudia Grauer, Martina Brueckmann, Marina Chernyatina, Geoffrey Donnan, José M Ferro, Martin Grond, Bernd Kallmünzer, Jerzy Krupinski, Byung-Chul Lee, Robin Lemmens, Jaime Masjuan, Miroslav Odinak, Jeffrey L Saver, Peter D Schellinger, Danilo Toni, Kazunori Toyoda, ,

BACKGROUND:Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran ... Read more >>

N. Engl. J. Med. (The New England journal of medicine)
[2019, 380(20):1906-1917]

Cited: 0 times

View full text PDF listing >>



High-Throughput Analysis of Optical Mapping Data Using ElectroMap.

Christopher O'Shea, Andrew P Holmes, Ting Y Yu, James Winter, Simon P Wells, Beth A Parker, Dannie Fobian, Daniel M Johnson, Joao Correia, Paulus Kirchhof, Larissa Fabritz, Kashif Rajpoot, Davor Pavlovic,

Optical mapping is an established technique for high spatio-temporal resolution study of cardiac electrophysiology in multi-cellular preparations. Here we present, in a step-by-step guide, the use of ElectroMap for analysis, quantification, and mapping of high-resolution voltage and calcium datasets acquired by optical mapping. ElectroMap analysis options cover a wide variety ... Read more >>

J Vis Exp (Journal of visualized experiments : JoVE)
[2019, (148):]

Cited: 0 times

View full text PDF listing >>



Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.

Dipak Kotecha, Jeroen J Bax, Céline Carrera, Barbara Casadei, Bela Merkely, Stefan D Anker, Panos E Vardas, Peter P Kearney, Marco Roffi, Michelle Ros, Alec Vahanian, Franz Weidinger, Ronen Beeri, Andrzej Budaj, Paolo Calabrò, Katarzyna Czerwińska-Jelonkiewicz, Flavio D'Ascenzi, Tom De Potter, Kevin F Fox, Juha Hartikainen, Brendan McAdam, Davor Milicic, Agnès A Pasquet, Alessandro Sionis, S M Afzal Sohaib, Costas Tsioufis, Patrick M J Verhorst, Paulus Kirchhof, , ,

AIMS:The provision of high-quality education allows the European Society of Cardiology (ESC) to achieve its mission of better cardiovascular practice and provides an essential component of translating new evidence to improve outcomes. METHODS AND RESULTS:The 4th ESC Education Conference, held in Sophia Antipolis (December 2016), brought together ESC education leaders, ... Read more >>

Eur. Heart J. (European heart journal)
[2019, 40(21):1728-1738]

Cited: 0 times

View full text PDF listing >>



Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet, Miriam Bach, Alexander G G Turpie, A John Camm,

AIMS:In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation (AF) is 20 mg once daily (o.d.), with 15 mg o.d. recommended in patients with creatinine clearance (CrCl) 15-49 mL/min. Non-recommended doses are prescribed in real-world practice. This analysis of the XANTUS study assessed outcomes associated with non-recommended dosing ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2019, 5(2):70-79]

Cited: 0 times

View full text PDF listing >>



Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.

Winnie Chua, Yanish Purmah, Victor R Cardoso, Georgios V Gkoutos, Samantha P Tull, Georgiana Neculau, Mark R Thomas, Dipak Kotecha, Gregory Y H Lip, Paulus Kirchhof, Larissa Fabritz,

AIMS:Undetected atrial fibrillation (AF) is a major health concern. Blood biomarkers associated with AF could simplify patient selection for screening and further inform ongoing research towards stratified prevention and treatment of AF. METHODS AND RESULTS:Forty common cardiovascular biomarkers were quantified in 638 consecutive patients referred to hospital [mean ± standard deviation age ... Read more >>

Eur. Heart J. (European heart journal)
[2019, 40(16):1268-1276]

Cited: 1 time

View full text PDF listing >>



Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).

Miklos Rohla, Thomas W Weiss, Ladislav Pecen, Giuseppe Patti, Jolanta M Siller-Matula, Renate B Schnabel, Richard Schilling, Dipak Kotecha, Markus Lucerna, Kurt Huber, Raffaele De Caterina, Paulus Kirchhof,

OBJECTIVES:We identified factors associated with thromboembolic and bleeding events in two contemporary cohorts of anticoagulated patients with atrial fibrillation (AF), treated with either vitamin K antagonists (VKA) or non-VKA oral anticoagulants (NOACs). DESIGN:Prospective, multicentre observational study. SETTING:461 centres in seven European countries. PARTICIPANTS:5310 patients receiving a VKA (PREvention oF thromboembolic ... Read more >>

BMJ Open (BMJ open)
[2019, 9(3):e022478]

Cited: 0 times

View full text PDF listing >>



Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.

Pier Luigi Temporelli, Roland R Tilz, Elena Arbelo, Nikolaos Dagres, Cécile Laroche, Harry J Crijns, Carina Blomstrom-Lundqvist, Paulus Kirchhof, Gregory Y H Lip, Giuseppe Boriani, Evengy Pokushalov, Eleni Nakou, Josep Brugada, Luigi Tavazzi,

Eur. J. Heart Fail. (European journal of heart failure)
[2019, 21(5):690-693]

Cited: 0 times

View full text PDF listing >>



The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients.

Peter Kearney, Maarten Simoons, Lars Ryden, Paulus Kirchhof, Axel Pries, Colm O'Morain, Jeroen J Bax,

Provision and participation in formal external continuing medical education (CME) is costly. Employer or state support of CME is the exception rather than the rule. The medical industry has supported both providers and consumers of educational activities, leading to concerns of commercial bias. Recent medical industry initiatives in Europe to ... Read more >>

Am. J. Med. (The American journal of medicine)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Cardiac Optogenetics and Optical Mapping - Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology.

Christopher O'Shea, Andrew P Holmes, James Winter, Joao Correia, Xianhong Ou, Ruirui Dong, Shicheng He, Paulus Kirchhof, Larissa Fabritz, Kashif Rajpoot, Davor Pavlovic,

Optogenetic control of the heart is an emergent technology that offers unparalleled spatio-temporal control of cardiac dynamics via light-sensitive ion pumps and channels (opsins). This fast-evolving technique holds broad scope in both clinical and basic research setting. Combination of optogenetics with optical mapping of voltage or calcium fluorescent probes facilitates ... Read more >>

Front Physiol (Frontiers in Physiology)
[2019, 10:182]

Cited: 0 times

View full text PDF listing >>



MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies.

Juliane Herm, Johannes Schurig, Martin R Martinek, Reinhard Höltgen, Alexander Schirdewan, Paulus Kirchhof, Marcus Wieczorek, Helmut Pürerfellner, Peter U Heuschmann, Jochen B Fiebach, Karl Georg Haeusler,

BACKGROUND:Atrial fibrillation (AF) without other stroke risk factors is assumed to have a low annual stroke risk comparable to patients without AF. Therefore, current clinical guidelines do not recommend oral anticoagulation for stroke prevention of AF in patients without stroke risk factors. We analyzed brain magnetic resonance imaging (MRI) imaging ... Read more >>

BMC Cardiovasc Disord (BMC cardiovascular disorders)
[2019, 19(1):58]

Cited: 0 times

View full text PDF listing >>



ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology.

Christopher O'Shea, Andrew P Holmes, Ting Y Yu, James Winter, Simon P Wells, Joao Correia, Bastiaan J Boukens, Joris R De Groot, Gavin S Chu, Xin Li, G Andre Ng, Paulus Kirchhof, Larissa Fabritz, Kashif Rajpoot, Davor Pavlovic,

The ability to record and analyse electrical behaviour across the heart using optical and electrode mapping has revolutionised cardiac research. However, wider uptake of these technologies is constrained by the lack of multi-functional and robustly characterised analysis and mapping software. We present ElectroMap, an adaptable, high-throughput, open-source software for processing, ... Read more >>

Sci Rep (Scientific reports)
[2019, 9(1):1389]

Cited: 1 time

View full text PDF listing >>



Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?

Luigi Di Biase, Paulus Kirchhof, Jorge Romero,

Europace (Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology)
[2019, 21(2):181-183]

Cited: 0 times

View full text PDF listing >>



Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.

Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W Weiss, Johannes Waltenberger, Jan Steffel, Joris R de Groot, Pierre Levy, Ameet Bakhai, Wolfgang Zierhut, Petra Laeis, Paul-Egbert Reimitz, Paulus Kirchhof, ,

AIM:Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor approved for the prevention of stroke and systemic embolism in adult patients with atrial fibrillation and for the treatment and secondary prevention in adult patients with venous thromboembolism (VTE). This study details the design of the Edoxaban ... Read more >>

J Cardiovasc Med (Hagerstown) (Journal of cardiovascular medicine (Hagerstown, Md.))
[2019, 20(2):97-104]

Cited: 0 times

View full text PDF listing >>



Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.

Giuseppe Patti, Ladislav Pecen, Markus Lucerna, Kurt Huber, Miklos Rohla, Giulia Renda, Jolanta Siller-Matula, Fabrizio Ricci, Paulus Kirchhof, Raffaele De Caterina,

BACKGROUND:The risks of thromboembolic and hemorrhagic events in patients with atrial fibrillation both increase with age; therefore, net clinical benefit analyses of anticoagulant treatments in the elderly population are crucial to guide treatment. We evaluated the 1-year clinical outcomes with non-vitamin-K antagonist and vitamin K antagonist oral anticoagulants (NOACs vs ... Read more >>

Am. J. Med. (The American journal of medicine)
[2019, 132(6):749-757.e5]

Cited: 0 times

View full text PDF listing >>



Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

A John Camm, Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet, Miriam Bach, Alexander G G Turpie,

AIMS:Based on Phase III data, non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with atrial fibrillation. To determine whether trial outcomes translate into similar event rates in unselected patients, this analysis compared outcomes from the real-world XANTUS study with those from the Phase III ROCKET AF ... Read more >>

Europace (Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology)
[2019, 21(3):421-427]

Cited: 0 times

View full text PDF listing >>



The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation.

Elton Amp Dudink, Bob Weijs, Samantha Tull, Justin Glm Luermans, Larissa Fabritz, Winnie Chua, Michiel Rienstra, Isabelle C Van Gelder, Ulrich Schotten, Paulus Kirchhof, Harry Jgm Crijns,

Background:Blood biomarkers related to AF could be useful to detect silent AF and to develop stratified strategies for AF prevention. Previous studies identified markers that predict incident AF. However, it is difficult to differentiate whether biomarkers relate to underlying cardiovascular diseases, are generated by the atria in response to an ... Read more >>

J Atr Fibrillation (Journal of atrial fibrillation)
[2018, 11(4):2058]

Cited: 0 times

View full text PDF listing >>



SMART About Watches: We Need Technical and Biological Validation of Atrial Fibrillation Screening.

Manish Kalla, Larissa Fabritz, Paulus Kirchhof,

JACC Clin Electrophysiol (JACC. Clinical electrophysiology)
[2019, 5(2):209-211]

Cited: 0 times

View full text PDF listing >>



Digital learning and the future cardiologist.

Xavier Rosselló, Mary Stanbury, Ronen Beeri, Paulus Kirchhof, Barbara Casadei, Dipak Kotecha,

Eur. Heart J. (European heart journal)
[2019, 40(6):499-501]

Cited: 0 times

View full text PDF listing >>



Development and validation of a score to detect paroxysmal atrial fibrillation after stroke.

Timo Uphaus, Mark Weber-Krüger, Martin Grond, Gerrit Toenges, Antje Jahn-Eimermacher, Marek Jauss, Paulus Kirchhof, Rolf Wachter, Klaus Gröschel,

OBJECTIVE:Prolonged monitoring times (72 hours) are recommended to detect paroxysmal atrial fibrillation (pAF) after ischemic stroke but this is not yet clinical practice; therefore, an individual patient selection for prolonged ECG monitoring might increase the diagnostic yield of pAF in a resource-saving manner. METHODS:We used individual patient data from 3 ... Read more >>

Neurology (Neurology)
[2019, 92(2):e115-e124]

Cited: 0 times

View full text PDF listing >>



Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.

Paulus Kirchhof, Miriam Bach, A John Camm,

J. Am. Coll. Cardiol. (Journal of the American College of Cardiology)
[2018, 72(20):2546-2547]

Cited: 0 times

View full text PDF listing >>



Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.

Jorge Romero, Roberto C Cerrud-Rodriguez, Juan Carlos Diaz, Gregory F Michaud, Jose Taveras, Isabella Alviz, Vito Grupposo, Luis Cerna, Ricardo Avendano, Saurabh Kumar, Paulus Kirchhof, Andrea Natale, Luigi Di Biase,

Aims:To assess the incremental benefit of uninterrupted direct oral anticoagulants (DOACs) vs. uninterrupted vitamin K antagonists (VKA) for catheter ablation (CA) of non-valvular atrial fibrillation (NVAF) on three primary outcomes: major bleeding, thrombo-embolic events, and minor bleeding. A secondary outcome was post-procedural silent cerebral infarction (SCI) as detected by brain ... Read more >>

Europace (Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology)
[2018, 20(10):1612-1620]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
2.1693 s